Showing results (251-260 of 410) with videos related to
Sort By:
Pageof 41
Cancer Letters|August 19, 2025
Targeting AXL can effectively overcome c-Met-induced therapeutic resistance in renal cancer and promote tumor cell death through increased oxidative stressAkash Sabarwal, Marc Machaalani, Laxminarayan Rawat, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2008
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study GroupDavid F McDermott, Jeffrey A Sosman, Rene Gonzalez, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2021
CDKN2A Alterations and Response to Immunotherapy in Solid TumorsElio Adib, Amin H Nassar, Elie W Akl, et al.Molecular Cancer Therapeutics|February 8, 2020
Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071Sophie Piperno-Neumann, James Larkin, Richard D Carvajal, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 20, 2025
Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-Risk MelanomaAhmad A Tarhini, Alyssa Obermayer, Sandra J Lee, et al.European Journal of Cancer (Oxford, England : 1990)|May 31, 2016
RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working GroupLawrence H Schwartz, Lesley Seymour, Saskia Litière, et al.Oncoimmunology|December 19, 2024
Circulating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumabJiajia Chen, Giuseppe Tarantino, Mariano Severgnini, et al.Blood|December 21, 2013
Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusionPavan Bachireddy, Ursula Hainz, Michael Rooney, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2018
Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 StudyMichael B Atkins, F Stephen Hodi, John A Thompson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2021
Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid TumorsGiuseppe Curigliano, Hans Gelderblom, Nicolas Mach, et al.Pageof 41